Navigation Links
Ireland Cancer Center researcher finds most triple-negative breast cancers express muc-1 target
Date:12/12/2008

CLEVELAND: Research out of the Ireland Cancer Center of University Hospitals Case Medical Center has found that the vast majority of triple negative breast cancers express the MUC-1 target. This first-of-its-kind finding, presented today at the San Antonio Breast Cancer Symposium, has paved the way for an upcoming vaccine trial for patients with early stage triple negative breast cancer that could potentially prevent recurrence of this aggressive type of breast cancer.

Joseph Baar, MD, PhD, Director of Breast Cancer Research at the Ireland Cancer Center, and colleagues analyzed 53 tumors and determined that 92 percent of them expressed MUC-1. These findings support their theory that this MUC-1 protein on breast cancer cells could be a target for a novel vaccine using the patient's immune system to target and kill cancer cells.

Dr. Baar has received a prestigious grant from the National Cancer Institute and the Avon Foundation to begin the vaccine trial in January 2009 for women with early stage triple negative breast cancer to see if this vaccine can raise their immune response against MUC-1. If it does, then a later study would be undertaken to determine whether the generation of such an immune response leads to an increase in patients' relapse-free survival rates, thereby preventing recurrence. The vaccine will be administered following standard therapy of surgery, radiation and chemotherapy.

"This vaccine trial has the potential to rev up patients' immune response to the MUC-1 protein and shut down the tumor's ability to grow," says Dr. Baar. "Women with this aggressive triple negative breast cancer have an increased risk of recurrence and we are hoping to provide them with protection against the return of this deadly disease. Our findings that have been presented at the San Antonio Breast Symposium provide us a strong basis for this trial."

Triple negative breast cancer is a highly aggressive form which comprises 10-15 percent of newly diagnosed early stage breast cancer. Most triple negative tumors are high grade and have a high incidence of recurrence and metastases (spreading to other organs). Unlike other types of breast cancer, there is no standard follow-up treatment for triple negative breast cancer to prevent recurrence.

"This is an important study because there has traditionally been nothing to offer women with triple negative breast cancer beyond standard therapy," says Stanton Gerson, MD, Director of the Ireland Cancer Center. "This vaccine trial has the potential to lay the groundwork for a new standard of care for women with this aggressive form of breast cancer."


'/>"/>

Contact: Alicia Reale
alicia.reale@UHhospitals.org
216-844-5158
University Hospitals of Cleveland
Source:Eurekalert

Related biology news :

1. Ireland Cancer Center researchers advance stem cell gene therapy
2. For good or ill Ireland gains another mammal species
3. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
4. A study by the MUHC and McGill University opens a new door to understanding cancer
5. ESF EURYI award winner aims to stop cancer cells reading their own DNA
6. Protein chatter linked to cancer activation
7. Newly created cancer stem cells could aid breast cancer research
8. Western diet linked to increased risk of colon cancer recurrence
9. Obesity and lack of exercise could enhance the risk of pancreatic cancer
10. Low levels of key protein may indicate pancreatic cancer risk
11. Birth records hold pancreatic cancer clue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2016)... A market that just keeps on growing. ... explosion in genomics knowledge. Learn all about it in ... of dynamic trends are pushing market growth and company ... pharmacogenomics - pathogen evolution - next generation sequencing - ... understanding of the role of genetic material in Disease ...
(Date:1/18/2016)... Jan. 18, 2016  Extenua Inc., a pioneering ... the use and access of ubiquitous on-premise and ... with American Cyber.  ... leading transformational C4ISR and Cyber initiatives in support ... latest proven technology solutions," said Steve Visconti ...
(Date:1/13/2016)... , January 13, 2016 ... the addition of the  "India Biometrics ... & Forecast (2015-2020)"  report to ... ) has announced the addition of ... Market - Estimation & Forecast (2015-2020)" ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... ... 09, 2016 , ... With a presidential election in November and the future ... bring together over 500 top healthcare leaders for a night and day of debates ... by MBA students of the University of Pennsylvania’s Wharton School, will be held February ...
(Date:2/9/2016)... ... , ... Date and time: March 1, 2016, 5:30 p.m. ... Center of Bucks County, 3805 Old Easton Road, Doylestown, PA 18902. , The ... open house for participants to learn about a new Master of Biomedical Science ...
(Date:2/9/2016)... ... 09, 2016 , ... Clinovo , the cloud-based eClinical ... Data Capture (EDC) system ClinCaptureand its new Contract Research Organization (CRO) Partner Program ... in San Mateo, California on February 10th and 11th. Watch 2-min video ...
(Date:2/9/2016)... ... February 09, 2016 , ... The American Academy ... history, it is offering its 2016 AAT Member Certification Qualification Course for Technicians via ... for the webinar, which will include a detailed review of hardware, software, and camera ...
Breaking Biology Technology: